.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the icon “BIOA,” according to files submitted along with the Stocks and also Swap Payment. The company has certainly not publicly shared an assumed monetary amount for the offering.The clinical-stage company touts lead prospect azelaprag, an orally provided little particle slated to get in period 2 testing in combination with semaglutide– sold through Novo Nordisk under brand name Wegovy for weight-loss– in the first half of following year. Semaglutide is actually also sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is made to integrate properly along with GLP-1 drugs, enhancing fat burning while keeping muscular tissue mass. The investigational medicine was located to be well-tolerated amongst 265 individuals all over 8 phase 1 tests, according to BioAge.Earlier, BioAge garnered the assistance of Lilly to run a trial mixing azelaprag with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro and also Zepbound for effective weight loss. The companions are currently conducting a stage 2 test of azelaprag as well as tirzepatide, with topline results assumed in the third fourth of 2025.The biotech is additionally organizing an insulin sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the very first fifty percent of upcoming year to sustain potential indicator development.
Additionally, the business prepares to talk to the FDA for authorization in the second fifty percent of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge’s anticipated relocate to everyone market adheres to a slight uptick in prepared biotech IPOs from Bicara Rehabs and also Zenas Biopharma. Zooming out, the recent IPO garden is a “blended photo,” with high quality firms still debuting on the general public markets, merely in lowered varieties, according to PitchBook.